Literature DB >> 21091647

Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal.

Yang-Sung Sohn1, Anna-Maria Mitterstiller, William Breuer, Guenter Weiss, Z Ioav Cabantchik.   

Abstract

BACKGROUND AND
PURPOSE: Systemic iron deficiency concomitant with macrophage iron retention is characteristic of iron-refractory anaemias associated with chronic disease. The systemic misdistribution of iron, which is further exacerbated by parenteral iron supplementation, is mainly attributable to iron retention exerted on resident macrophages by hepcidin-mediated down-regulation of the iron exporter ferroportin. We aimed at developing an experimental macrophage-based cell model that recapitulates pathophysiological features of iron misdistribution found in chronic disorders and use it as a screening platform for identifying agents with the potential for relocating the accumulated metal and restoring affected functions. EXPERIMENTAL APPROACH: A raw macrophage subline was selected as cell model of iron retention based on their capacity to take up polymeric iron or aged erythrocytes excessively, resulting in a demonstrable increase of cell labile iron pools and oxidative damage that are aggravated by hepcidin. KEY
RESULTS: This model provided a three-stage high throughput screening platform for identifying agents with the combined ability to: (i) scavenge cell iron and thereby rescue macrophage cells damaged by iron-overload; (ii) bypass the ferroportin blockade by conveying the scavenged iron to other iron-starved cells in co-culture via transferrin but (iii) without promoting utilization of the scavenged iron by intracellular pathogens. As test agents we used chelators in clinical practice and found the oral chelator deferiprone fulfilled essentially all of the three criteria. CONCLUSIONS AND IMPLICATIONS: We provide a proof of principle for conservative iron relocation as complementary therapeutic approach for correcting the misdistribution of iron associated with chronic disease and exacerbated by parenteral iron supplementation.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21091647      PMCID: PMC3188895          DOI: 10.1111/j.1476-5381.2010.01120.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy.

Authors:  W Breuer; M J Ermers; P Pootrakul; A Abramov; C Hershko; Z I Cabantchik
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

2.  Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.

Authors:  Hava Glickstein; Rinat Ben El; Maya Shvartsman; Z Ioav Cabantchik
Journal:  Blood       Date:  2005-07-14       Impact factor: 22.113

3.  Oxidative damage to proteins: spectrophotometric method for carbonyl assay.

Authors:  A Z Reznick; L Packer
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

4.  Sulforhodamine B assay and chemosensitivity.

Authors:  Wieland Voigt
Journal:  Methods Mol Med       Date:  2005

Review 5.  Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD.

Authors:  Jodie L Babitt; Herbert Y Lin
Journal:  Am J Kidney Dis       Date:  2010-02-26       Impact factor: 8.860

6.  Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism.

Authors:  G Lescoat; K Chantrel-Groussard; N Pasdeloup; H Nick; P Brissot; F Gaboriau
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

7.  Absence of functional Hfe protects mice from invasive Salmonella enterica serovar Typhimurium infection via induction of lipocalin-2.

Authors:  Manfred Nairz; Igor Theurl; Andrea Schroll; Milan Theurl; Gernot Fritsche; Ewald Lindner; Markus Seifert; Marie-Laure V Crouch; Klaus Hantke; Shizuo Akira; Ferric C Fang; Günter Weiss
Journal:  Blood       Date:  2009-08-21       Impact factor: 22.113

8.  Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation.

Authors:  Or Kakhlon; Hila Manning; William Breuer; Naomi Melamed-Book; Chunye Lu; Gino Cortopassi; Arnold Munnich; Z Ioav Cabantchik
Journal:  Blood       Date:  2008-09-16       Impact factor: 22.113

9.  The co-ordinated regulation of iron homeostasis in murine macrophages limits the availability of iron for intracellular Salmonella typhimurium.

Authors:  Manfred Nairz; Igor Theurl; Susanne Ludwiczek; Milan Theurl; Sabine M Mair; Gernot Fritsche; Günter Weiss
Journal:  Cell Microbiol       Date:  2007-04-25       Impact factor: 3.715

10.  Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias.

Authors:  Elizabeta Nemeth
Journal:  Adv Hematol       Date:  2009-12-24
View more
  15 in total

Review 1.  Perspective: What Makes It So Difficult to Mitigate Worldwide Anemia Prevalence?

Authors:  Klaus Schümann; Noel W Solomons
Journal:  Adv Nutr       Date:  2017-05-15       Impact factor: 8.701

Review 2.  Drug Repurposing in Parkinson's Disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

3.  NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth.

Authors:  Yang-Sung Sohn; Sagi Tamir; Luhua Song; Dorit Michaeli; Imad Matouk; Andrea R Conlan; Yael Harir; Sarah H Holt; Vladimir Shulaev; Mark L Paddock; Abraham Hochberg; Ioav Z Cabanchick; José N Onuchic; Patricia A Jennings; Rachel Nechushtai; Ron Mittler
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

4.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

Authors:  David Devos; Caroline Moreau; Jean Christophe Devedjian; Jérome Kluza; Maud Petrault; Charlotte Laloux; Aurélie Jonneaux; Gilles Ryckewaert; Guillaume Garçon; Nathalie Rouaix; Alain Duhamel; Patrice Jissendi; Kathy Dujardin; Florent Auger; Laura Ravasi; Lucie Hopes; Guillaume Grolez; Wance Firdaus; Bernard Sablonnière; Isabelle Strubi-Vuillaume; Noel Zahr; Alain Destée; Jean-Christophe Corvol; Dominik Pöltl; Marcel Leist; Christian Rose; Luc Defebvre; Philippe Marchetti; Z Ioav Cabantchik; Régis Bordet
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

5.  Intracellular Iron Binding and Antioxidant Activity of Phytochelators.

Authors:  Fredson Torres Silva; Breno Pannia Espósito
Journal:  Biol Trace Elem Res       Date:  2021-10-14       Impact factor: 3.738

6.  The Fe-S cluster-containing NEET proteins mitoNEET and NAF-1 as chemotherapeutic targets in breast cancer.

Authors:  Fang Bai; Faruck Morcos; Yang-Sung Sohn; Merav Darash-Yahana; Celso O Rezende; Colin H Lipper; Mark L Paddock; Luhua Song; Yuting Luo; Sarah H Holt; Sagi Tamir; Emmanuel A Theodorakis; Patricia A Jennings; José N Onuchic; Ron Mittler; Rachel Nechushtai
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-11       Impact factor: 11.205

7.  Cp/Heph mutant mice have iron-induced neurodegeneration diminished by deferiprone.

Authors:  Liangliang Zhao; Majda Hadziahmetovic; Chenguang Wang; Xueying Xu; Ying Song; H A Jinnah; Jolanta Wodzinska; Jared Iacovelli; Natalie Wolkow; Predrag Krajacic; Alyssa Cwanger Weissberger; John Connelly; Michael Spino; Michael K Lee; James Connor; Benoit Giasson; Z Leah Harris; Joshua L Dunaief
Journal:  J Neurochem       Date:  2015-09-29       Impact factor: 5.372

Review 8.  Cancer cells with irons in the fire.

Authors:  Laura M Bystrom; Stefano Rivella
Journal:  Free Radic Biol Med       Date:  2014-05-14       Impact factor: 7.376

9.  On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.

Authors:  D J Pennell; J P Carpenter; M Roughton; Zi Cabantchik
Journal:  J Cardiovasc Magn Reson       Date:  2011-09-12       Impact factor: 5.364

Review 10.  Labile iron in cells and body fluids: physiology, pathology, and pharmacology.

Authors:  Zvi Ioav Cabantchik
Journal:  Front Pharmacol       Date:  2014-03-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.